With CBD Products Unlawful, FDA Enforcement Policy Guidance Has No Economic Significance
As draft guidance receives OMB review, FDA’s determination of no economic significance reflects its official position that the thousands of supplements, food and personal care products containing CBDs available in the US are unlawful.
You may also be interested in...
Supplements containing hemp-derived cannabidiols aren’t typical products subject to FDA’s regulatory oversight, and the document stating its thinking on enforcement in the market submitted to the Office of Management and Budget isn’t a typical draft guidance.
Appropriation Committee members target $5m for FDA's CBD policy work and suggest the agency enforce against noncompliant firms in their report accompanying legislation proposing the agency’s fiscal 2021 budget.
US cannabis research funding of $189m, growing 65% since 2016, isn’t keeping pace with demand for CBD products with sales projected to surpass $20bn by 2024, says the Collaborative for CBD Science and Safety. It urges industry to accelerate R&D and FDA to move forward with a regulatory framework.